46.41 USD
▲+1.52+3.39%
盘后 47.08 +1.44%
2026-11-19
市值
$3.42B
市盈率
—
EPS
-1.69
股息率
—
52 周区间
14.79 – 62.32
成交量
993.37K
Beta
0.36
目标价
74.33
52W 低 14.7952W 高 62.32
价格走势
公司简介
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe...